Tg Therapeutics Stock Earnings Reports

TG Therapeutics reported an exceptional Q1 2026 driven by strong commercial execution for BRIUMVI. U.S. net product revenue was approximately $195M (above guidance) and total global revenue was ~$205M; management is raising full-year U.S. revenue guidance to $885M–$900M and total global revenue guidance to ~$925M. Key commercial metrics: >25,000 patients prescribed globally, 12 consecutive quarters of sequential growth, record new patient starts, and improving persistence—supporting a recurring revenue base and an expected near-term annualized run rate approaching $1B. Pipeline and lifecycle highlights: near-term topline readouts expected (ENHANCE Phase III on consolidated IV dosing and Phase I bioavailability for subcutaneous), ENHANCE data due in the coming weeks with potential regulatory filing/launch of consolidated IV dosing if positive; subcutaneous Phase III is fully enrolled with topline expected around year-end/early next year and a target commercial launch in 2028 if approved. Management frames subcutaneous BRIUMVI as materially expanding the addressable market (potentially nearly doubling it) by enabling entry into the ~35% subcutaneous anti-CD20 segment. Other development programs include planned Phase II in myasthenia gravis, an exploratory study in treatment-resistant schizophrenia, and ongoing dose-escalation work with azer-cel (allogeneic anti-CD19 CAR-T) in progressive MS. Financial/capital allocation: operating income improved (Q1 operating income $34.8M), net income $19.8M ($0.12/share); cash and investments ~ $573M at quarter end after expanding the Blue Owl facility; repurchased ~$100M of stock in the quarter (~6.8M shares total repurchased to date, ~5% of shares outstanding). Full-year operating costs expected ~ $350M (ex-stock comp) plus ~$100M for subcutaneous manufacturing/start-up. Key near-term investor catalysts: ENHANCE topline, subcutaneous Phase I bioavailability release, subcutaneous Phase III topline, and additional azer-cel updates later this year. Risks noted include standard regulatory, clinical and market competition uncertainties and usual forward-looking statement caveats.